{
    "nctId": "NCT04281355",
    "briefTitle": "Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy",
    "officialTitle": "Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy: The EUBREAST-2 INDAX Trial",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "iDFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with primary invasive breast cancer cT1-cT3\n* cN1 status prior to PST\n* Cytological or histological proof of axillary metastasis before PST\n* Full tumour biology available before initiation of PST\n* Oral and written consent\n* Age \u2265 18 years\n\nExclusion Criteria:\n\n* Biopsy-confirmed regional nodal metastases outside of the ipsilateral axilla\n* Distant metastases at diagnosis\n* Inflammatory breast cancer\n* Previous axillary surgery\n* Previous radiotherapy to ipsilateral breast, chest or axilla\n* History of prior invasive breast cancer\n* Ongoing pregnancy or breast-feeding\n* Bilateral invasive breast cancer\n* Medical contraindication for radiotherapy or inability to receive recommended radiotherapy\n* Medical contraindication for adjuvant endocrine treatment, if indicated\n* Inability to absorb or understand the meaning of the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}